

US EPA ARCHIVE DOCUMENT

TO: PM-17

SUBJECT: 432-667
 Scourge Insecticide with SBP-1382/Piperonyl
 Butoxide 18% + 54% MF Formula II
 Penick Corporation
 1050 Wall Street
 Lyndhurst, NJ 07071

In TSS: 07-16-84
 Record No.: 125299
 Accession No.: 252817
 Action: 305

FORMULATION: Liquid Concentrate.

Active Ingredients:

Resmethrin.....	18.00%
Related Compunds.....	2.45%
PBO, Technical.....	54.00%
Aromatic Petroleum Solvent.....	24.67%
Inert Ingredients.....	0.88%

BACKGROUND: Registrant has submitted a new Eye Irritation test. They claimed that a mix-up of samples had occurred in their original eye study which placed this product in Toxicity Category I for eye irritation potential (see Hutton review of October 4, 1983).

SUBMITTED DATA: Study was conducted at:

M. B. Research Laboratories
 Steinsburg and Wentz Roads
 Spinnerstown, PA 18968

1. Primary eye irritation. Project #MB 83-6999D, submitted 02-13-84. Six albino rabbits received 0.1 ml in one eye of each rabbit. Treated eyes were not washed. Fluorescein scan was used post-test. Observations were made at 1 hour, and 1, 2, and 3 days. There was no corneal opacity. Mild to medium conjunctival redness, chemosis and discharge was noted, clearing in 5/6 eyes by day 3. No further observations were made.

Study classification: Core minimum data.
 Product classification: Toxicity category III.

COMMENTS:

1. This eye irritation study is acceptable and on the basis of this study, product has been placed in category III.
2. The following changes are required in precautionary labeling:
 - a. Change signal word to "Warning" (on the basis of skin irritation category II per Hutton review of 10-04-83).
 - b. Change "Avoid contact with skin, eyes, or clothing" to "Causes skin irritation. Do not get on skin, in eyes, or on clothing. Wash thoroughly with soap and water after handling. Remove contaminated clothing and wash before reuse."
 - c. Delete "if irritation persists" from statement of Practical Treatment for skin.
3. Registrant should address acute inhalation toxicity and dermal sensitization potential.

Rita Kumar
IRB/TSS

Rita Kumar